Bellevue Group AG Acquires 4,636 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bellevue Group AG boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 17.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 31,412 shares of the biopharmaceutical company's stock after buying an additional 4,636 shares during the quarter. Bellevue Group AG's holdings in Regeneron Pharmaceuticals were worth $22,376,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in REGN. Pamalican Asset Management Ltd bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $4,915,000. Intact Investment Management Inc. purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $356,000. Rhenman & Partners Asset Management AB increased its position in Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after buying an additional 4,457 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after buying an additional 2,828 shares during the period. Finally, Fagan Associates Inc. lifted its position in shares of Regeneron Pharmaceuticals by 42.2% during the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock valued at $9,205,000 after buying an additional 3,832 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on REGN shares. Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective on the stock. JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a research report on Monday, March 31st. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their price target for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Finally, Sanford C. Bernstein cut their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $892.60.

Regeneron Pharmaceuticals Stock Up 2.6 %

Shares of REGN opened at $605.61 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $525.99 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a 50 day simple moving average of $626.49 and a two-hundred day simple moving average of $709.39. The firm has a market cap of $66.21 billion, a P/E ratio of 15.82, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the prior year, the business posted $9.55 EPS. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.